I've interpreted Zweig's approach a bit differently than AAII, but at the core of both screens is a method for identifying financially sound growth companies and not overpaying for them.
"We desperately need a method to distinguish which mutations are driving the tumor's growth and which are mere hitchhikers, " says Sloan-Kettering's Michor.